WtBKER, Institut fur Strahlenbiologie, Universitat Munster.
The production of single strand breaks (SSBs) and double strand breaks (DSBs) in T2 DNA (16 ,ug/ml) by bleomycin (Bi) (40 ,g/ml) was investigated quantitatively. At 5°C 0.11 SSB/min per T2 genom were found. The addition of 1 mmol cysteamine (SH) enhances the single strand breakage rate by a factor of 25. DSBs were found at a rate of 0-5/min only in the presence of SH and Bi. Since the accidental DSB rate due to SSBs in opposite DNA strands is less than 10-3/min per T2 genom DSBs must be produced directly by the action of Bi. The obtained DNA profiles did not follow a random distribution; thus bleomycin apparently acts at specific sites along the T2 genom. Xirradiation followed by BI-SH treatment resulted in an increased DNA degradation. The number of SSBs is at least 3 times larger than expected if the effect of both treatments is just additive. Skin reactions occurring on the legs of mice after 230 kV x-irradiation were used to investigate the combined effects of x-irradiation and bleomycin. Bleomycin was given daily for 5 days (5 mg/kg/day), either preceding or following graded single doses of x-rays. Skin reactions occurring after combined treatment were compared with skin reactions produced by x-irradiation alone. Both bleomycin schemes yielded average 1-30 day post-irradiation skin reactions greater than skin reactions seen after xirradiation alone. Dose-response curves for the combined treatments were parallel to the x-irradiation alone treatment, but were displaced upwards. The responses obtained in the 2 bleomycin schemes were not significantly different. The dose modifying effect of the bleomycin treatments ranged from 1-5 at low levels of effect to 1 2 at higher levels of effect. It is concluded that the combined effects of bleomycin and x-irradiation in this design were additive. In a second series of experiments, the ability of bleomycin to affect the ability of mouse skin to recovery from radiation injury in a fractionated experiment (3F/4D) was studied. Bleomycin was found to apparently decrease, by about 30%0, the repair of sublethal radiation damage when given simultaneously with the radiation exposure (5 mg/kg).
MODIFICATION OF THE RESPONSE
RADIATION AND ANTI-TUMOUR DRUGS. M. BARKER-GRIMSHAW, K. HELL-MANN and G. E. MURKIN, Chemotherapy Department, Imperial Cancer Research Fund, London.
Growth inhibitory effects of the antitumour drugs 5-flourouracil, adriamycin, hydroxyurea, bleomycin, cyclophosphamide, methotrexate, ICRF 159 and 593A and the radiosensitizer Ro-07-0582 combined with a standard dose of radiation was tested on the radiosensitive sarcoma 180. The most effective potentiators were 593A and ICRF 159. They were then examined against the relatively radioresistant Lewis lung carcinoma and melanoma B16 using either single doses of drug and radiotherapy or the same total dose given in fractions over 5 days. 593A was equally potent whether given as a single maximum tolerated dose or in divided doses; ICRF 159 was ineffective when given as a single low dose (though it was effective given in a single high dose), but highly effective in divided low doses. Clinical trials with ICRF 159 in combination with radiotherapy are in progress.
EFFECT OF LUCANTHONE ON THE RADIOSENSITIVITY OF A MOUSE TUMOUR. K. R. RAO and H. FRITZ-NIGGLI, Radiobiology Institute of Zurich University.
Lucanthone is reported to be carcinostatic (Hirschberg et al., J. natn. Cancer Inst., 1959, 22, 567 ) and a radiosensitizer (Bases, Cancer Res., 1970 , 30, 2007 . But in our study lucanthone alone (70 mg/kg body weight) had no lasting effect on the Ehrlich carcinoma in mice. Based on mitotic studies, 4-day old ascites tumour was not sensitized to x-rays when pretreated with lucanthone. Tumour growth, evaluated as the average weight of solid tumours or the number of tumour cells in ascites bearing mice, was not significantly different between the group treated with x-rays only and the one treated with lucanthone plus x-rays. Thus, lucanthone seems to enhance the radiosensitivity of normal cell
